An important step in poliovirus (PV) infection by the oral route in humans is replication of the virus in lymphatic tissues of the gastrointestinal (GI) tract, thought to be mainly in the Peyer's patches of the small intestine. No immunocompetent transgenic (tg) mice that express human PV receptor (CD155) under the control of different promoters can be infected orally. The mouse orthologue of human CD155 is Tage4, a protein expressed at the surface of enterocytes and in the Peyer's patches. We describe here the generation of a tg mouse model in which the Tage4 promoter was used to drive expression of the human PV receptor-coding region (Tage4-CD155tg mice). In this model, CD155 expression was observed by immunostaining in different regions in the Peyer's patches but not in their germinal centres. Although a similar pattern of staining was observed between 3-and 6-week-old Tage4-CD155tg mice, poliomyelitis was only seen in the younger mice after PV infection by the oral route. When compared with TgPVR21 mice that expressed CD155 driven by its human promoter, 3-week-old Tage4-CD155tg mice were more susceptible to gut infection and paralysis following feeding with PV. Also, Tage4-CD155tg mice exhibited higher susceptibility to poliomyelitis after parenteral inoculation of PV. Remarkably, the LD 50 after intracerebral inoculation of PV was similar in both CD155 tg mouse strains. The CD155 tg mouse model reported here, although moderately susceptible to oral infection, may be suitable to study mechanisms of PV replication in the gastrointestinal tract and to dissect important aspects of PV neuroinvasiveness.
INTRODUCTION
Poliovirus (PV), discovered more than 100 years ago (Landsteiner & Popper, 1909) , is an RNA virus belonging to the genus Enterovirus of the family Picornaviridae. PV is the causative agent of poliomyelitis, a neurological disease that leads to the destruction of motor neurons resulting in paralysis of the limbs, and in some cases loss of breathing control and even death (Bodian, 1959; Mueller et al., 2005) . PV infection is initiated by oral ingestion of the virus followed by multiplication in the orogastrointestinal tract and faecal shedding. Viraemia is common but is not a requirement for efficient virus proliferation (Bodian, 1955; Sabin, 1956) . Indeed, viraemia precedes the invasion of the central nervous system (CNS) (Mueller et al., 2005) . Although the precise sites and cell types involved in the primary replication are not known, PV has generally been isolated in lymphoid organs associated with the orogastrointestinal tract, particularly the Peyer's patches, an observation suggesting that replication in these tissues is paramount to PV pathogenesis (Bodian, 1955; Sabin, 1956; Siciń ski et al., 1990) . Unfortunately, this phase of PV infection and the stages immediately following are poorly understood. Non-human primate models for poliomyelitis have been used extensively due to their natural susceptibility to infection with PV (Bodian, 1959; Mueller et al., 2005) . Although much has been learned primarily from infections of cynomolgus monkeys, a lack of awareness of virus-specific proteins and of the virus receptor, combined with the lack of useful reagents (i.e. mAbs), has hindered the progress of dissecting PV infections. Currently, the cost and regulatory issues associated with primate research have made the study of PV pathogenesis impractical. also known as PV receptor (PVR) Koike et al., 1994) . The isolation and characterization of human CD155 (Koike et al., 1990; Mendelsohn et al., 1989; Wimmer et al., 1994) eventually led to the generation of CD155 transgenic (tg) mice (Koike et al., 1991; Ren et al., 1990) . These mice are susceptible to infection by parenteral routes and show a neuronal histopathology similar to that of primates (Crotty et al., 2002; Ida-Hosonuma et al., 2002; Koike et al., 1991 Koike et al., , 1994 Ren et al., 1990; Yanagiya et al., 2003; Zhang & Racaniello, 1997) . However, these mice at 3 weeks of age or older are resistant to oral infection, which is the primary route of infection in humans. It was hypothesized that the inability of these tg mice to be infected orally is due to a difference in expression of CD155 in the tissues of the alimentary tract of mice and humans Koike et al., 1994) . CD155 is expressed in gut-associated lymphoid tissues, specifically on human follicle-associated epithelium (FAE), on microfold (M) cells and in the germinal centres (GCs) of the Peyer's patches and tonsils Lange et al., 2001) . In TgPVR21 mice, a strain of the CD155 tg mouse generated by Koike et al. (1991) , CD155 expression was barely detected in the cells of the gastrointestinal tract except in the tunica muscularis . The lack of receptor expression on cells of the alimentary tract may explain the lack of susceptibility/resistance of these tg mice to oral infection.
There have been several attempts to express CD155 in the alimentary tract of mice by producing CD155 under the control of diverse promoters, such as the human CD155 promoter (Koike et al., 1991) , b-actin promoter (Crotty et al., 2002) , intestinal fatty acid binding protein promoter (Zhang & Racaniello, 1997) , specific for intestinal enterocytes, CAG promoter (combination of the cytomegalovirus early enhancer element and chicken b-actin promoter) (IdaHosonuma et al., 2002) , and the nectin-2 promoter, which was originally assumed to be the human CD155 homologue (Yanagiya et al., 2003) . Unfortunately, none of these attempts was able to yield a mouse model that was sensitive to oral infection, even though, remarkably, in some of these tg mice, human CD155 was expressed on the surface of mouse enterocytes (Crotty et al., 2002; Yanagiya et al., 2003; Zhang & Racaniello, 1997) . Interestingly, TgPVR21 mice backcrossed with IFN-a/b receptor knockout mice (TgPVR21/ ifnar KO) were susceptible to oral infection and exhibited more widespread dissemination than in non-immunocompromised animals (Ohka et al., 2007) . The uncontrolled PV replication in these IFN-a/b-deficient mice causes severe lesions in tissues that are not susceptible to PV infection in immunocompetent humans, non-human primates and mice (Ida-Hosonuma et al., 2005; Ohka et al., 2007) . Overall, a suitable immunocompetent mouse model for analysing the early events in PV pathogenesis following oral inoculation has not yet been constructed.
The mouse orthologue of human CD155 has been identified as Tage4, a prominent cell-surface protein expressed in rat colon and mammary carcinoma cells and later also identified in mice (Chadéneau et al., 1994; Ravens et al., 2003) . Tage4 and CD155 have a conserved gene structure and both are localized on the syngeneic chromosome in mice (Baury et al., 2001) . Although Tage4 shares only 42 % amino acid similarity with CD155, all critical protein domains are conserved in both proteins, such as the Tctex-1-binding motif and the tyrosine-containing binding motif of the m1B subunit of the clathrin adaptor complex within the cytoplasmic tail. Most importantly, CD155 and Tage4 are expressed in the alimentary tract of humans and mice in a similar pattern, respectively Ravens et al., 2003) , i.e. on enterocytes, the FAE and the M cells of the Peyer's patches.
Based on these observations, we reasoned that the lack of expression of CD155 in the mouse alimentary tract could be overcome by expressing the PV receptor under the control of the mouse promoter of the Tage4 gene. The aim of these studies was to generate a new transgenic mouse model (Tage4-CD155tg) in which the Tage4 promoter drove the expression of CD155. We were successful in expressing CD155 in the alimentary tract but only 3-week-old or younger mice were susceptible to PV infection via the oral route. After virus feeding, virus replication was detected in the small intestine, followed by paralysis of the animals. Moreover, Tage-CD155tg mice were significantly more susceptible to paralysis than TgPVR21 mice after parenteral PV inoculations. Our results indicate that the PV receptor tg mice reported here could be used to characterize the replication of PV in gut mucosa and extraneural tissues.
RESULTS
Expression of CD155 and PV replication in the intestine of Tage4-CD155tg mice Tage4-CD155tg mice were generated using a fusion gene cosmid containing a Tage4 promoter and CD155 coding region to generate a mouse with a CD155 protein distribution similar to Tage4 (Fig. 1) . CD155 expression in the Peyer's patches of Tage4-CD155tg mice was analysed by immunofluorescence. The tissue samples were stained with CD155 and CD23 antibodies to detect the PV receptor and mature resting follicular B-cells, respectively.
A consistent expression of CD155 was observed in the tunica muscularis (Fig. 2) . Moreover, the receptor was clearly detected but was scattered in the subepithelial dome among the follicular B-cells outside the GC (Fig. 2) . A more pronounced staining was observed in the interfollicular region but rarely within the FAE of Peyer's patches (Fig. 2) . CD155 expression, however, was barely detectable in the GC (Fig. 2) . In addition, the lamina propria of the surrounding villi also contained CD155-expressing cells (Fig. 2) . Expression of CD155 was not detected in the small intestine of control ICR mice (data not shown). There was no age-dependent difference in the expression of CD155 in the 3-or 6-week-old Tage4-CD155tg mice (data not shown).
To assess the ability of PV to replicate in the gastrointestinal tract, 3-week-old mice were fed 10 10 p.f.u. virus, and virus titres in the faeces and small intestine were determined at different times after administration of virus (Figs 3 and 4) (Fig. 3) . Thereafter, the viral titres decreased progressively, with a more pronounced decline in virus level observed in TgPVR21 mice than in Tage4-CD155tg mice (P,0.05 at day 2; Fig. 3 Site-directed mutagenesis 100 mm 100 mm (a) Fig. 2 . Expression of CD155 in Peyer's patches of Tage4-CD155tg mice. Peyer's patches were collected from 6-week-old Tage4-CD155 mice. The tissue section (b) was stained with affinity-purified rabbit polyclonal antiserum against CD155 (red) and CD23 (green). Nuclei were stained with DAPI (blue). The control section (a) was stained only with secondary antibody. L, lumen; SED, subepithelial dome; IFR, interfollicular region; TM, tunica muscularis. Fig. 3 . Titres of PV in faeces after oral administration of PV. Virus was isolated from faeces of 3 -week-old Tage4-CD155 tg, TgPVR21 or ICR mice. Mice from each strain were orally administered with 4¾10 9 p.f.u. PV. After administration of the virus inoculum (day 0), viral titres were determined, as described in Methods, in faeces collected on days 1, 2 and 3 after oral infection. Each column represents the mean±SD of values from four individual mice. An asterisk indicates a significant difference at P,0.05.
2 and 3 days p.i. from control ICR mice (Fig. 3) . Similarly, small intestine viral titres were highest at 1 day p.i., and then decreased in both transgenic mouse strains (Fig. 4) . The viral titres observed were always higher in the small intestine from the Tage4-CD155tg mice than those from TgPVR21 mice, and this difference was statistically significant at 1 and 2 days p.i. (Fig. 4) . When compared with tg mice, much lower viral titres were observed in the faeces and small intestine from control ICR mice at 1 day p.i., probably representing a portion of the inoculum; thereafter, no virus was detected in these mice (Fig. 4) .
These results indicated that expression of the PV receptor in the mouse intestinal tract can support a discrete but measurable level of PV replication after oral infection. These data also showed that Tage4-CD155tg mice are more susceptible to PV oral infection than TgPVR21 mice.
Susceptibility of Tage4-CD155tg and TgPVR21 mice to poliomyelitis after PV inoculation by the oral route
We determined susceptibility to paralysis in both CD155 tg mice strains after oral PV infection. Interestingly, there were no differences in susceptibility to poliomyelitis between 1-week-old Tage4-CD155tg and TgPVR21 mice (Table 1 ). An increase in resistance to oral infection with PV was observed in 3-week-old mice when compared with 1-week-old mice of both strains (Table 1) . The 1-week-old Tage4-CD155tg mice showed a 50 % paralysis and lethal dose (PLD 50 ) value that was 10 000-fold lower than the 3-week-old mice (Table 1) . We were able to determine the PLD 50 for 3-week-old Tage4-CD155tg mice but not the exact value of PLD 50 for 3-weekold TgPVR21 mice (Table 1) . However, at the highest dose of PV tested (10 10 p.f.u.), 100 % of the Tage4-CD155tg mice showed paralysis and died within 8 days, whilst only 20 % of the TgPVR21 mice died (P,0.01, Fig. 5) . Hence, at 6 weeks of age, mice from both strains were found to be resistant to oral infection at 10 10 p.f.u., the highest dose tested (Table 1) . Control ICR mice were not susceptible to oral infection at any age.
In contrast, a similar clinical pattern was observed in both CD155 tg mouse strains. Flaccid paralysis developed in 81 % of the infected mice, whilst 19 % of the inoculated animals died before signs of clinical disease could be recorded. Both the forelimb and hindlimb were affected in almost equal numbers of cases. No difference in incubation period was observed between the two strains of tg mice.
Susceptibility of Tage4-CD155tg and TgPVR21 to poliomyelitis after PV inoculation by the parenteral route
We also tested the ability of the mice to be infected by intracerebral (i.c.), intramuscular (i.m.), intravenous (i.v.) and intraperitoneal (i.p.) routes. Mice were susceptible to infection by all parenteral routes ( Table 2 ). The Tage4-CD155tg mice were at least 10-fold more susceptible to poliomyelitis after i.c. infection than by other routes (Table  2 ). For i.m. infection, paralysis was consistently seen initially in the leg that was inoculated. All routes of infection . Titres of PV in the small intestine after oral administration of PV. Virus was isolated from the small intestine of 3-week-old Tage4-CD155 tg, TgPVR21 or ICR mice. Mice from each strain were orally administered with 4¾10 9 p.f.u. PV. After administration of the virus inoculum (day 0), four mice from each group were sacrificed daily, and virus titres in the small intestine were determined by plaque assay, as described in Methods. Each column represents the mean±SD of values from four individual mice. An asterisk indicates a significant difference at P,0.05. Polio in mice expressing CD155 under control of Tage4 eventually led to paralysis and death, as observed previously with TgPVR21 mice (Koike et al., 1994) .
The Tage4-CD155tg mice were 1000-, 100-and 10-fold more susceptible to infection than the TgPVR21 mice by i.p., i.v. and i.m. routes, respectively (Table 2 ). Mice were significantly less susceptible to paralysis by the oral route than by the parenteral routes (Tables 1 and 2 ). As observed in orally inoculated mice, no difference in clinical pattern was detected between Tage4-CD155tg and TgPVR21 mice infected via different parenteral routes.
DISCUSSION
Studies of poliomyelitis have been instrumental in unravelling many aspects of viral diseases (Mueller et al., 2005) . However, important questions of PV pathogenesis have yet to be elucidated. Non-human primates can develop acute flaccid paralysis that closely mimics poliomyelitis in humans after oral infection with PV (Bodian, 1955 (Bodian, , 1972 Sabin, 1956) . The use of these animals for experimental work is expensive, cumbersome and increasingly subject to restrictions. Currently, the only available animal models for PV are based on transgenic mice that carry the human PV receptor CD155 gene (Crotty et al., 2002; Ida-Hosonuma et al., 2002; Koike et al., 1991; Ren et al., 1990; Yanagiya et al., 2003; Zhang & Racaniello, 1997) . However, these tg mice have to be infected via parenteral routes as they are resistant to oral infection, the natural route of transmission in humans (Crotty et al., 2002; Koike et al., 1991; Ren et al., 1990; Zhang & Racaniello, 1997) . Therefore, the greatest challenge of studying poliomyelitis in mice has been the expression of a functional receptor mediating PV replication in the gastrointestinal tract.
Here, we have described a new tg mouse line expressing CD155 under the Tage4 promoter, the mouse orthologue of the human PV receptor. In contrast to the lack of CD155 expression observed in TgPVR21 mice by Iwasaki et al. (2002) , we detected moderate expression of the PV receptor in the subepithelial dome, FAE and interfollicullar cell region of Peyer's patches of Tage4-CD155tg mice. In both tg mice, however, CD155 staining in GCs of the Peyer's patches was almost negligible, whilst strong expression of CD155 was detected in the tunica muscularis. Our previous and current results indicate that the correlation between CD155 expression and susceptibility to oral infection in mouse models is complex (Iwasaki et al., 2002) . The higher level of expression of CD155 observed in Tage4-CD155tg mice correlated with a higher susceptibility to oral infection when compared with TgPVR21 mice at the age of 3 weeks. Nonetheless, and despite different patterns of CD155 expression, both strains of tg mice were equally susceptible or resistant to PV oral infection at 1 and 6 weeks, respectively. The Tage4-CD155tg mice tested in this study were heterozygous for CD155. Therefore, it is tempting to speculate that Tage4-CD155tg mice homozygous for CD155 might be more susceptible to oral infection than Tage4-CD155tg mice heterozygous for CD155 due to the gene dose effect.
Several tg mouse strains expressing CD155 (including TgPVR21 mice) have been deemed resistant to oral infection by PV (Koike et al., 1991; Ren et al., 1990; Crotty et al., 2002; Zhang and Racaniello, 1997 ). This conclusion is based on experimental infections carried out using 3-week-old or older mice. Remarkably, we observed an increased resistance to oral infection between 3-and 6-week-old Tage4-CD155tg mice without any noticeable change in CD155 expression in the Peyer's patches. It is clear from our study that the outcome of PV infection by the oral route depends not only on CD155 expression in the gut tissue but also on other host factors related to the age of the infected mice.
Neonatal and infant mammals are more susceptible than adult mammals to infections (Fenner, 1968; Maró di, 2006; Sigel, 1952) . Immaturity of anatomical barriers and immune system has been postulated to contribute to the increased vulnerability of younger hosts to infections (Adkins et al., 2004; Lecce, 1972; Levy, 2007; Maheshwari and Zemlin, 2006; Moog, 1951; Moog & Grey, 1967) . All organ systems of the body experience an important transition at birth, which is followed by age-dependent maturation (Levy, 2007; Maheshwari & Zemlin, 2006; Moog, 1951; Moog & Grey, 1967) . In mice, barrier effect and clearance mechanisms become apparent at 14-18 days of age (Lecce, 1972) . These data may indicate that the oral susceptibility to PV reported here in both 1-week-old CD155 transgenic mouse strains is a consequence of immature defensive mechanisms that fail to prevent PV spreading from the gut mucosa to the CNS, rather than the result of virus-specific replication in the small intestine. In line with this hypothesis, Loria et al. (1976) reported that intestinal resistance against oral infection with coxsackie B virus is age dependent. It has been shown that intestinal microbiota can modulate enteric PV replication (Kuss et al., 2011) . Therefore, an intriguing possibility is that a change in the gut microbiome during these stages might also regulate the growth of PV in the small intestine.
Remarkably, TgPVR21 mice back-crossed with TgPVR21/ ifnar KO mice are susceptible to PV oral infection (Ohka et al., 2007) . One hundred per cent of TgPVR21/ifnar KO and 80 % of Tage4-CD155tg mice showed paralysis and died after PV oral inoculation of 3610 8 and 1610 10 p.f.u., respectively. These results indicate that IFN-a/b deficient mice are more susceptible to PV oral infection than immunocompetent PVRTg21. Ohka et al. (2007) showed that, in et al., 2007) . These studies demonstrate that IFN-a/b plays an important role in tissue restriction and pathogenicity of PV in vivo. As stated by Ohka et al. (2007) , however, human PVR-tg/ifnar KO is not a good animal model for analysing PV tropism after oral inoculation due to the unrestricted virus replication in target and non-target tissues (Ohka et al., 2007) . Nevertheless, studies using IFN-a/b-deficient mice clearly indicate that the virus also has to overcome the innate immunity to establish a productive infection in the gut. As described above, there is a physiological maturation of the immune response with age. Therefore, neonate (1-week-old) and infant (3-week-old) mice are also more susceptible to oral infection than adult (6-week-old) mice due to a transiently impaired innate immune response at the mucosal level.
In contrast, on entry into the body PV multiplies in the lymphoid tissues of the gut, particularly in the Peyer's patches (Bodian, 1955; Sabin, 1956) . Moreover, CD155 is the major determinant of PV tropism (Koike et al., 1991; Mendelsohn et al., 1989; Ren et al., 1990; Wimmer et al., 1994) . Although CD155 is expressed in the Peyer's patches of Tage4-CD155tg mice and macaque rhesus monkeys , adult animals of these species are resistant to gut infection. It should be noted that expression of CD155 in the GC of the Peyer's patches of these animals was absent or barely detectable. In contrast, CD155 is prominently expressed in the GC of Peyer's patches and on endothelial cells within Peyer's patches in humans, the most susceptible mammal to oral PV infection . It has been shown that Tage4 is not expressed on mouse GC B-cells (Ravens et al., 2003) . This observation may explain why the mouse Tage4 promoter did not drive the expression of CD155 in the GC of Peyer's patches of Tage4-CD155tg mice (Fig. 2) . Moreover, PV replication was not observed in tg mice expressing high levels of CD155 in the intestinal epithelial cells (Zhang & Racaniello, 1997) . Collectively, these data suggest that CD155 expression in the GC and endothelial cells of Peyer's patches may be an important factor required for a productive PV infection of the gastrointestinal tract.
Altogether, our data and results from other investigations (cited above) indicate that the establishment of a productive PV infection by the oral route in the mouse models is the result of an interplay between mucosal defence mechanisms, which mature with age, and an effective virus replication, which depends on CD155 expression in the Peyer's patches.
Contrary to the small difference observed in neurovirulence between Tage4-CD155tg and TgPVR21 mice after PV feeding, the former were significantly more susceptible to CNS infection than the latter by i.p., i.m. and i.v. routes.
However, both transgenic mice showed similar LD 50 values following i.c. inoculation.
The capacity of PV to infect the CNS after peripheral inoculation is associated mainly with the ability of the virus to replicate in the cells of the mononuclear phagocyte system (lymph nodes, bone marrow, liver and spleen) (Bodian, 1959 (Bodian, , 1972 Sabin, 1956 ). The mononuclear phagocyte system is a diffuse system consisting of phagocytic cells, bone marrow monoblasts and pro-monocytes, peripheral blood monocytes and tissue macrophages. Interestingly, peritoneal macrophages and B-cells of CD155 tg mice and human monocytes and their derivatives (macrophages and dendritic cells) are productively infected by PV (Buisman et al., 2003; Freistadt & Eberle, 1996 Freistadt et al., 1993; Wahid et al., 2005) . Taking into account these data, one can speculate that the significant difference in susceptibility to PV neuroinvasion between the CD155 tg mouse strains studied here after parenteral virus inoculation reflects a more efficient replication of PV in the mononuclear phagocyte system of the Tage4-CD155tg mice than that in the TgPVR21 mice. Therefore, our findings might suggest that the expression levels of CD155 in mouse mononuclear phagocytes may be higher when driven by the mouse homologue promoter than by the human promoter of the transgene. This hypothesis warrants further studies.
In contrast, it has been observed that there is a marked difference in disease susceptibility among different inbred strains of mice inoculated with PV2 (Jubelt et al., 1991) . Tage4-CD155tg and TgPVR21 mice are constructed in different genetic backgrounds. Hence, we cannot rule out the possibility that the genetic background of the hosts might also contribute to the difference in susceptibility to PV infection observed between the mouse strains studied here.
Although the adult Tage4-CD155tg mice studied here were resistant to oral infection by PV, young animals (3 weeks old) of this tg mouse strain are moderately susceptible to the mucosal route of infection. Age is a major determinant of PV infection outcome (Nathanson & Kew, 2010) . Moreover, young children are probably the most important transmitters of PV (Nathanson & Kew, 2010) . Hence, our results indicate that the 3-week-old Tage4-CD155tg mice can be used to dissect mechanisms of PV replication in the gastrointestinal tract, dissemination from the gut mucosa into the CNS and virus transmission via the faecal-oral route. In addition, we postulate that Tage-CD155tg mice are a sensitive animal model to study in detail important aspects of neuroinvasiveness of PV following systemic replication.
METHODS
Cells and viruses. HeLa R19 and mouse Ltk 2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10 % FBS and 1 % penicillin/streptomycin.
The virulent PV type 1 (Mahoney) strain was grown on HeLa R19 cells and was employed in this study.
Polio in mice expressing CD155 under control of Tage4
Cosmid generation. The Tage4 promoter was amplified from clone CAAA01210663 (Ravens et al., 2003) by PCR using forward primer 59-CACCTAAGGCTAGCCCAAACTCTCTCAC-39 and reverse primer 59-GAGCCATAAGCTTCCGGTCCGATCCAG-39 (Fig. 1) . The underlined positions denote NheI and HindIII restriction sites introduced for the ease of cloning. Using NheI and HindIII restriction sites, the 2.5 kb Tage4 promoter was cloned into the multiple cloning site of pGL3-Basic, a promoterless luciferase expression vector (clone 1-1). The 800 bp sequence containing exon 1 of the CD155 gene using forward primer 59-AGCAAAGCTTATGGCCCGAGCCATGG-39 and reverse primer 59-GGTCAGAGGGGTTCTAGAGTCAAGT-GTC-39 was amplified from pTL-HC5 (Koike et al., 1990) , where underlined sequences denote HindIII and XbaI cleavage sites. The PCR product and clone 1-1 were treated with HindIII and XbaI, and the products were ligated giving rise to clone 1-2, containing the Tage4 promoter and 800 bp of exon 1 of CD155. Site-directed mutagenesis was then used to restore the CD155 sequence upstream of ATG, in the process destroying the HindIII site introduced to ligate the Tage4 promoter and exon 1 of the CD155 gene. The primers for the site-directed mutagenesis were sense primer 59-TGGATCGG-ACCGGAACCACATGGCCCGAGCCATG-39 and antisense primer 59-CATGGCTCGGGCCATGTGGTTCCGGTCCGATCCA-39. Through PCR, the mCD155 promoter and exon 1 of CD155 fragment were amplified using forward primer 59-CTTACGGATCCTAGCCCAA-ACTCTC-39 and reverse primer 59-CTGCTAGCTTATGGCCTGG-GTATG-39. The underlined sequences represent the BamHI and NheI restriction sites. The PCR product was then inserted into a SuperCos-1 vector using restriction sites BamHI and XbaI for the SuperCos-1 vector and BamHI and NheI for the PCR product (clone 2-1). Clone 2-2 was constructed by cutting the cos sequence of the SuperCOS-1 vector with BamHI and XbaI, which then was ligated into the pCDNA 3.1(+) vector.
ApaI/PinAI (AgeI)-digested clone 2-1 (including the Tage4 promoter and exon 1), AgeI/NheI-digested pTL-HC5 (containing the CD155 structural gene) and NheI/SphI-digested clone 2-2 (containing the cos sequence) were ligated and packaged using Gigapack III XL Packaging Extract (Stratagene). Escherichia coli JM109 cells were infected with the phage particles carrying the cosmid clone of the Tage4-CD155 fusion gene.
Generation of Tage4-CD155tg mice. Tage4, the mouse orthologue of CD155, has an expression profile similar to CD155 in humans (Baury et al., 2001; Ravens et al., 2003) . Therefore, we constructed a fusion gene cosmid containing a Tage4 promoter and the CD155 coding region in order to generate a tg mouse with a CD155 protein distribution similar to that of Tage4. The generation of the fusion gene is illustrated in Fig. 1 . This fusion gene carries a 2.5 kb upstream sequence of Tage4 and a 30 kb sequence of the CD155 coding region (Fig. 1) .
The Tage4-CD155 cosmid was linearized with NotI to remove all exogenous bacterial vector sequence. The linearized DNA was introduced into pronuclei of Taconic ICR mouse zygotes. Mice were screened for the transgene by PCR to amplify~600 bp within the intron 5 and exon 6 with forward primer 59-CTTGTCTCTGC-TTTTCGTTA-39 and reverse primer 59-CAGCACAGAGCCCGTAG-TAG-39. As a result, a new tg mouse line constructed in an ICR background, Tage4-CD155tg, was established. The tg mouse line was maintained in the heterozygous stage. TgPVR21 mice (Koike et al., 1991) were maintained at the homozygous stage. The TgPVR21 mice were constructed in the C57B1/6 background. All mice used had been maintained under specific-pathogen-free conditions and were treated in strict compliance with guidelines established by Stony Brook University, NY, USA.
Multiple-colour immunofluorescence staining of tissues. To examine the distribution of CD155 expression, frozen sections of the small intestine were stained using CD155 and CD23 antibodies by a procedure similar to that described by Iwasaki & Kelsall (2000) with minor modifications. In brief, 6-8 mm frozen tissue sections on glass slides were fixed in cold acetone and blocked with TNB buffer (NEN Life Science Products) containing 5 % normal donkey serum. The sections were further treated with an avidin/biotin kit (Vector Laboratories) to block endogenous biotin. Endogenous peroxidase activity was quenched with 1 % H 2 O 2 for 10 min, and purified polyclonal rabbit CD155 antiserum was added for 1.5 h at room temperature. Slides were washed and incubated with biotin-conjugated donkey F(ab9) 2 anti-rabbit IgG (Jackson ImmunoResearch Laboratories) for 30 min, followed by incubation with a streptavidin-HRP conjugate (Zymed Laboratories). The antigens were detected with either tetramethylrhodamine-tyramide or FITC-tyramide (NEN Life Science Products), according to the manufacturer's instructions. In the case of double labelling on the same section, the sections were treated with 2 % H 2 O 2 for 10 min, followed by blocking with avidin/biotin and incubation with 100 mg mouse IgG (Sigma-Aldrich) ml 21 for 20 min and, finally, with F(ab9) 2 goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) for 20 min. The second primary antibody against CD23 (eBioscience) was then added to the sections for 1.5 h. At the end of the staining, the slides were washed and incubated with DAPI for nuclear staining (Molecular Probes). Slides were mounted with Fluoromount G (Southern Biotechnology Associates) and analysed with a Leitz Orthoplan 2 fluorescence microscope or by confocal microscopy with a Zeiss LSM510 confocal microscope.
Administration of PV. I.m. administration was carried out as 100 ml injections into the thigh of the right hind leg using a 27.5-gauge syringe. I.p. administrations were carried out as 100 ml injections using an insulin syringe. Before i.c. administrations were carried out, animals were anaesthetized with a solution of ketamine (10 mg ml 21 ) and xylazine (0.2 mg ml 21 ) in saline. I.c. injections were administered as 30 ml injections into the mid-brain using a 27.5-gauge syringe. I.v. inoculations were carried out as 100 ml tail vein injections using a 27.5-gauge syringe after warming the mice for 20 min under a heating lamp.
In 1-week-old mice, 100 ml virus was administered orally by depositing the inoculum into the mouth using a gavage needle. In mice of 3 weeks and older, the virus was administered orally using a water bottle. The mice were given 4 ml virus solution in DMEM within 24 h using the water bottle. All mice were observed and scored twice daily for at least 21 days for signs or symptoms of disease: abnormal gait, lethargy, ruffled fur, arched back, paresia, flaccid paralysis and death (Cello et al., 2002; Gromeier & Wimmer, 1998) . In parallel, we also infected TgPVR21 mice. For the determination of PLD 50 , mice were inoculated by all routes of infection with viral doses ranging from 10 1 to 10 10 p.f.u. Four mice per dose were infected and the PLD 50 was calculated by the method of Reed and Muench (Cello et al., 2002) . For the survival test, 10 Tage4-CD155tg and 10 TgPVR21 3-week-old mice were infected orally with 10 10 p.f.u. and observed for signs and symptoms of disease for 21 days.
Isolation and titration of PV from small intestine and faeces.
For determination of virus titre in the small intestine, mice were infected orally with the virus and tissues from four mice of each strain were collected on days 1, 2 and 3 p.i. Briefly, the mice were anaesthetized and whole blood was recovered from the right ventricle. Immediately, the mice were perfused with saline through the left ventricle and the small intestines were excised. The tissues were homogenized in DMEM to prepare 10 % emulsions. The 10 % emulsions were freeze-thawed three times. The homogenates were centrifuged to remove any debris, and the supernatant containing the virus was subjected to a plaque assay as described previously (Pincus et al., 1986) .
To monitor PV replication in the mouse gastrointestinal tract, faeces were collected from four mice at various times after oral inoculation. For every volume of faeces, 10 vols PBS and 1 vol. chloroform were added. The solution was mixed by vortexing, and debris was pelleted at 1800 g for 10 min. The supernatant was collected and virus titres were determined by a plaque assay (Pincus et al., 1986) .
Statistical analysis. A t-test was used to determine the significance of the mean titre of virus isolated from the small intestine and faeces. Life expectancies between groups of mice were estimated by the Kaplan-Meier method. Statistical significance in the two groups of mice was compared using the log-rank test. P,0.05 was considered statistically significant.
